UPC APP 13067/2025

—·EP3175863: VARIANTS OF C-TYPE NATRIURETIC PEPTIDE

Case details: Status
—
Action
Preliminary objection
Category
Preliminary Objection
Parties: Claimants
BioMarin Pharmaceutical Inc.
Reps: Christian Paul (Jones Day); Tobias Mandler (Jones Day); Pascal Grandé (Jones Day); Jason Raeburn (Paul Hastings); Alex Morgan (Paul Hastings)
Respondents
Ascendis Pharma A/S
Ascendis Pharma Growth Disorders A/S
Reps: Agathe Michel-De Cazotte (Carpmaels & Ransford); Anna Leathley (Carpmaels & Ransford); Daniel Wiese (Carpmaels & Ransford)
Division: Munich LD
Judges: Matthias Zigann · Presiding judge and judge-rapporteur
Technology: Biotechnology
Language: —
First decided: Apr 2, 2025

Decisions

2025-04-02
JurisdictionalPreliminary objection
The Munich Local Division rejected Ascendis Pharma's preliminary objection to jurisdiction in the infringement action brought by BioMarin Pharmaceutical concerning EP 3 175 863 (C-Type Natriuretic Peptide variants for achondroplasia treatment). The court found that the opt-out withdrawal was effective and that sufficient acts of infringement were alleged in Germany.
Legal issues:Preliminary objection to jurisdictionOpt-out withdrawalActs of infringement in GermanyAchondroplasia treatmentTransCon CNP

Documents